Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19341844 | 0.83 | ALDH1A1 (0.46) | ALDH1A1TSHRRELALMNATDP1 | |
| SCHEMBL16755617 | 0.79 | TDP1 (0.43) | ALDH1A1TDP1CYP3A4KDM4EL3MBTL1 | |
| SCHEMBL20025824 | 0.74 | CYP2C19 (0.44) | ALDH1A1TSHRLMNATDP1CYP3A4 | |
| SCHEMBL1177035 | 0.73 | ALDH1A1 (0.59) | ALDH1A1TSHRRELAPSMD14LMNA | |
| SCHEMBL8035043 | 0.73 | ALDH1A1 (0.59) | ALDH1A1TSHRPSMD14LMNATDP1 | |
| SCHEMBL12114947 | 0.73 | ALDH1A1 (0.59) | ALDH1A1TSHRRELAPSMD14LMNA | |
| SCHEMBL99027 | 0.73 | ALDH1A1 (0.59) | ALDH1A1TSHRRELAPSMD14LMNA | |
| SCHEMBL98719 | 0.73 | ALDH1A1 (0.59) | ALDH1A1TSHRPSMD14LMNATDP1 | |
| SCHEMBL4112398 | 0.73 | ALDH1A1 (0.59) | ALDH1A1TSHRPSMD14LMNATDP1 | |
| SCHEMBL172194 | 0.73 | ALDH1A1 (0.59) | ALDH1A1TSHRRELAPSMD14LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260305-A1 | LIGAND COMPOUND, CATALYST SYSTEM FOR OLEFIN OLIGOMERIZATION, AND METHOD FOR OLIGOMERIZING OLEFINS USING THE SAME | LG CHEM, LTD. (KR) | 2017-09-14 | — | — | US | disclosed |
| EP-3208284-A1 | LIGAND COMPOUND, CATALYST SYSTEM FOR OLEFIN OLIGOMERIZATION, AND METHOD FOR OLIGOMERIZING OLEFINS USING THE SAME | LG Chem, Ltd. (KR) | 2017-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260305-A1 | LIGAND COMPOUND, CATALYST SYSTEM FOR OLEFIN OLIGOMERIZATION, AND METHOD FOR OLIGOMERIZING OLEFINS USING THE SAME | OXER1, OSTC, OCIAD1 | ALDH1A1 607/4885TSHR 3604/4885RELA 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.